Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02900716
Title Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zhejiang DTRM Biopharma
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.